The benefits of exposure therapy alone may last longer than sertraline alone or sertraline plus exposure therapy in social phobia


QUESTION: Do the benefits of exposure therapy and sertraline for social phobia last after treatment has ceased?

Design
Randomised controlled trial with allocation concealment. Physicians and patients were blind to pharmacological treatment allocation (but not psychosocial treatment).

Setting
Norway and Sweden; timeframe not specified.

Participants
375 people aged 18–65 years with generalised social phobia of at least 1 year duration (DSM-IV criteria) rated as moderately ill (score of 4 or greater on overall severity item of the Clinical Global Impression - Social Phobia scale, severity sub-scale). Participants were recruited from 41 primary care centres in Norway and Sweden and from advertisements in newspapers and other media. 61% were female; mean age was 40 years; mean age at symptom onset was 16 years; mean duration of illness was 24 years. People with comorbid dysthymia or specific phobias were eligible. People with panic disorder with onset before social phobia or any other current anxiety or major depressive disorder were excluded, as were people with substance misuse, eating disorder or a history of bipolar disorder or psychosis.

Intervention
Participants received sertraline or placebo for 24 weeks, with or without 8 short sessions of exposure therapy provided by general practitioners (2 x 2 design). After treatment was discontinued, participants entered a 28 week follow up period where additional treatment could be provided at the clinicians’ discretion. About 20% received treatment with sertraline during the follow up period, 8% received exposure treatment and 7% referral to a psychologist or psychiatrist. Participants were evaluated at baseline, at the completion of treatment and 52 weeks after inclusion (follow up rate 87%).

Main outcome measures
The main outcome measure was change in symptoms and severity scores using the 36-item Short Form Health Survey and the Clinical Global Impression - Social Phobia scale. General practitioners evaluated their own patients at 24 and 52 weeks.

Main results
During the treatment period, sertraline, exposure therapy, and combined treatment with sertraline and exposure therapy were all associated with reduced social phobia scores. Treatment with exposure therapy alone was associated with subsequent improvement, whereas people who received sertraline had a tendency towards deterioration after medication ceased. People who received exposure therapy had improved social phobia scores during follow up (mean change in overall severity score 0.45, 95% CI 0.16 to 0.65, P < 0.01). At 52 weeks, those receiving sertraline alone or sertraline plus exposure therapy had a greater deterioration on the 36-item Short Form Health Survey compared with exposure therapy alone.

Conclusions
Exposure therapy alone may have ongoing benefits for people with social phobia. There was a tendency towards deterioration after completing treatment with sertraline alone or exposure therapy combined with sertraline. The authors conclude that exposure therapy administered alone is more effective in the long term than when combined with sertraline.